Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -42.05% is in line with its 5-year average of -45.26%, near the high end of its 5-year range (-168.37%–-2.72%).
As of the fiscal period ended Monday, June 30, 2025. 28.36% below its 12-month average of -32.76%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2025-06-30.
RETURN ON EQUITY (ROE)
-42.05%
RETURN ON EQUITY (ROE) AVG TTM
-32.76%
RETURN ON EQUITY (ROE) AVG 3Y
-25.11%
RETURN ON EQUITY (ROE) AVG 5Y
-45.26%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-28.36%
CURRENT VS 3Y AVG
-67.43%
CURRENT VS 5Y AVG
+7.09%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-37.66%
median of 436 covered companies
CURRENT VS SECTOR MEDIAN
-11.66%
vs the sector median at left
Gelteq Limited Ordinary Shares
Market Cap
$4.99M
Return on Equity (ROE)
-42.05%
TTM Avg
-32.76%
3Y Avg
-25.11%
5Y Avg
-45.26%
Market Cap
$4.96M
Return on Equity (ROE)
-248.66%
TTM Avg
-110.63%
3Y Avg
-33.84%
5Y Avg
-33.84%
Market Cap
$4.85M
Return on Equity (ROE)
-385.27%
TTM Avg
175.03%
3Y Avg
3.40%
5Y Avg
-11.76%
Market Cap
$4.79M
Return on Equity (ROE)
-30.74%
TTM Avg
235.96%
3Y Avg
-836.91%
5Y Avg
-570.34%
Market Cap
$5.21M
Return on Equity (ROE)
-351.30%
TTM Avg
-321.98%
3Y Avg
-228.03%
5Y Avg
-177.46%
Market Cap
$5.36M
Return on Equity (ROE)
-156.77%
TTM Avg
-655.11%
3Y Avg
-353.82%
5Y Avg
-293.10%
Market Cap
$4.46M
Return on Equity (ROE)
-239.95%
TTM Avg
-454.28%
3Y Avg
-297.70%
5Y Avg
-194.53%
Market Cap
$5.54M
Return on Equity (ROE)
-225.57%
TTM Avg
-289.16%
3Y Avg
-245.03%
5Y Avg
-192.04%
Market Cap
$4.42M
Return on Equity (ROE)
-424.89%
TTM Avg
-156.14%
3Y Avg
-97.37%
5Y Avg
-86.32%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gelteq Limited Ordinary Shares (GELS) | $4.99M | -42.05% | -32.76% | -25.11% | -45.26% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $4.96M | -248.66% | -110.63% | -33.84% | -33.84% |
| CalciMedica, Inc. (CALC)vs › | $4.85M | -385.27% | 175.03% | 3.40% | -11.76% |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.79M | -30.74% | 235.96% | -836.91% | -570.34% |
| Imunon, Inc. (IMNN)vs › | $5.21M | -351.30% | -321.98% | -228.03% | -177.46% |
| Alzamend Neuro Inc (ALZN)vs › | $5.36M | -156.77% | -655.11% | -353.82% | -293.10% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.46M | -239.95% | -454.28% | -297.70% | -194.53% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.54M | -225.57% | -289.16% | -245.03% | -192.04% |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.42M | -424.89% | -156.14% | -97.37% | -86.32% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.41M | -383.03% | -1602.50% | -1094.59% | -783.90% |
ROE
-42.0%
ROA
-30.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-06-30 | -42.05% |
| 2024-06-30 | -23.47% |
| 2023-06-30 | -18.79% |
| 2022-06-30 | -16.15% |
| 2021-06-30 | -2.72% |
| 2020-06-30 | -168.37% |
